Intended Use & Indications Toolkit
Intended use statement, indications for use, scope analysis, EU MDR intended purpose, change impact assessment, and contraindications documentation — drafted to FDA and EU MDR submission standards.
What You Get
Intended Use Statement Template (FDA 510k Format)
Template for drafting FDA-compliant intended use statements for 510k premarket notification submissions. Covers the five required elements: device type, target patient population, body part or tissue, clinical application, and user qualifications. Includes the FDA distinction between intended use (broader) and indications for use (more specific), and the common drafting errors that cause FDA to request a narrowed or clarified intended use statement.
Indications for Use Statement Template (21 CFR 801.4)
Structured template for indications for use statements aligned with 21 CFR 801.4 and FDA 510k requirements. Covers the intended patient population, disease or condition, intended use environment, and contraindications. Pre-formatted for inclusion in the 510k Indications for Use form (FDA Form 3881) and the device labeling indications section.
Intended Use Scope Analysis Worksheet
Structured analysis worksheet for evaluating the breadth and boundaries of your intended use claim. Covers on-label vs off-label use distinction, the implications of broad vs narrow intended use claims for predicate matching and clinical data requirements, the intended user analysis, and the risk-benefit considerations that influence intended use scope decisions before 510k submission.
EU MDR Intended Purpose Statement Template (Article 2(12))
Intended purpose statement template aligned with EU MDR Article 2(12) definition covering all required elements: specific medical purpose, target patient population, intended users, clinical conditions, organs or body parts involved, and intended use environment. Includes guidance on how the EU MDR intended purpose statement differs from FDA intended use and drives GSPR compliance demonstration.
Intended Use Change Impact Assessment Template
Structured assessment for evaluating the regulatory impact of a proposed change to an existing device's intended use. Covers the substantial equivalence implications of intended use changes for 510k-cleared devices, the EU MDR technical documentation update requirements, the labeling change obligations, and the CAPA linkage when intended use modifications arise from post-market feedback.
Contraindications, Warnings, and Precautions Documentation Template
Template for documenting contraindications, warnings, and precautions as part of the intended use package. Covers the FDA labeling requirements under 21 CFR Part 801, the EU MDR Annex I GSPR 23 labeling requirements, risk-benefit basis for each contraindication, and the clinical evidence linkage that supports the warning and precaution statements in your device labeling.
FAQ
What is the difference between intended use and indications for use?
Intended use is the general purpose of the device as reflected in the labeling claims (broader). Indications for use is a more specific subset describing the disease, condition, or patient population for which the device is used. FDA requires both for 510k submissions via FDA Form 3881.
Can I expand my intended use after 510k clearance?
Expanding intended use generally requires a new 510k submission. Intended use changes are one of the seven categories FDA evaluates when determining whether a device modification requires a new submission. Changes that broaden the patient population, clinical application, or clinical setting typically require new clearance.
What format are the documents?
All documents are editable Word templates ready for direct use.
Ready to get started?
For informational purposes only. Not legal or regulatory advice. Legal